- Home
- TENX vs MURA Comparison
TENX vs MURA Comparison
Compare TENX & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- MURA
- Stock Information
- Founded
- TENX 1967
- MURA 2013
- Country
- TENX United States
- MURA Ireland
- Employees
- TENX N/A
- MURA N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- MURA
- Sector
- TENX Health Care
- MURA
- Exchange
- TENX Nasdaq
- MURA Nasdaq
- Market Cap
- TENX 21.6M
- MURA 17.7M
- IPO Year
- TENX N/A
- MURA N/A
- Fundamental
- Price
- TENX $5.68
- MURA $2.56
- Analyst Decision
- TENX Strong Buy
- MURA Strong Buy
- Analyst Count
- TENX 3
- MURA 4
- Target Price
- TENX $16.00
- MURA $13.00
- AVG Volume (30 Days)
- TENX 12.6K
- MURA 1.1M
- Earning Date
- TENX 05-14-2025
- MURA 05-20-2025
- Dividend Yield
- TENX N/A
- MURA N/A
- EPS Growth
- TENX N/A
- MURA N/A
- EPS
- TENX N/A
- MURA N/A
- Revenue
- TENX N/A
- MURA N/A
- Revenue This Year
- TENX N/A
- MURA $34.35
- Revenue Next Year
- TENX N/A
- MURA N/A
- P/E Ratio
- TENX N/A
- MURA N/A
- Revenue Growth
- TENX N/A
- MURA N/A
- 52 Week Low
- TENX $2.77
- MURA $0.95
- 52 Week High
- TENX $7.89
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- TENX 49.30
- MURA 53.24
- Support Level
- TENX $5.49
- MURA $2.48
- Resistance Level
- TENX $5.87
- MURA $2.72
- Average True Range (ATR)
- TENX 0.27
- MURA 0.10
- MACD
- TENX 0.03
- MURA 0.02
- Stochastic Oscillator
- TENX 52.04
- MURA 33.88
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.